Objective: Angiotensin-converting enzyme (ACE) inhibitors have beneficial effects on arterial compliance and distensibility and favourably modify the arterial pressure waveform in hypertensive patients. The objective of our study was to explore the possible effects of adding an ATII AT 1 receptor antagonist to an ACE inhibitor on augmentation pressure, a measure of arterial stiffness, and pulse pressure amplification in patients with poorly controlled essential hypertension. Design and methods: We studied a group of 18 patients with poorly controlled hypertension, despite at least three antihypertensive drugs including an ACE inhibitor, before, at 2 h and 2 weeks following the administration of 80 mg of valsartan, an ATII AT 1 receptor antagonist. Haemodynamic responses were measured by cuff sphygmomanometry, arterial pulse-wave analysis and the pulse pressure gradient was calculated as the difference between the brachial pulse pressure (cuff sphygmomanometry) and derived aortic pulse pressure (arterial pulse wave analysis). Results: Blood pressure decreased significantly (P Ͻ 0.001) and the effect was more pronounced on central
Introduction
Arterial stiffness is increasingly recognised as an independent risk factor for cardiovascular disease 1 and contributes to the development of hypertension 2 and left ventricular hypertrophy. 3 In young subjects, arterial wave reflection (AWR) is timed to return to the ascending aorta during diastole, after ventricular ejection has ceased. Such timing is desirable since the rise in pressure in the ascending aorta in diastole not only boosts coronary perfusion pressure but also avoids an increase in left ventricular afterload. The diastolic timing of AWR in the ascending aorta has implications for the peripheral circulation; the pulse amplifies between central and peripheral arteries, systolic blood pressure (SBP) being +12 to +20 mm greater in the radial artery than in the aorta. 4, 5 However, as arteries stiffen, especially in hypertension, pulse wave velocity increases, causing the reflected wave to return to the ascending aorta earlier, during systole. Such early wave reflection leads to an increase in SBP, pulse pressure (PP) and decreased pressure throughout diastole. Increase in SBP leads to increased myocardial oxygen demands, whereas a fall in diastolic blood pressure (DBP) leads to decreased coronary perfusion, both predisposing to myocardial ischaemia. Furthermore, increased SBP leads to increased left ventricular afterload, generating left ventricular hypertrophy. 5 The ill effects of early AWR also necessarily include a loss of pulse pressure amplification between cen-Journal of Human Hypertension tral and peripheral arteries. This disappearance of the pulse pressure gradient along the arterial tree is a predictor of cardiovascular risk, especially for coronary artery disease, in both the normotensive and hypertensive population. 6 The technique of pulse wave analysis 7 allows the non-invasive recording of arterial pressure waveforms by the method of applanation tonometry. 8 The radial artery pressure wave can be recorded quite accurately and when calibrated against the brachial blood pressure values, is used to derive the ascending aortic pressure waveform. The ascending aortic waveform can provide important information regarding the effects of early wave reflection on the aortic blood pressure curve, quantified in absolute terms as augmentation pressure (Aug) and as augmentation index (AIx) when expressed as a percentage of PP. Also, the derived aortic PP can be used to calculate the PP gradient between the radial artery and aorta. 9 Early wave reflection certainly has adverse haemodynamic consequences and delaying it would be logical therapy in the management of hypertension and left ventricular hypertrophy. [10] [11] [12] [13] [14] [15] Attention is being directed at drugs that reduce early AWR and arterial stiffness, as not all antihypertensives have a beneficial effect on arterial stiffness and AWR despite the same level of blood pressure reduction. 16, 17 Angiotensin-converting enzyme (ACE) inhibitors, in particular, have been shown to delay AWR and increase the pulse pressure gradient between the central and peripheral circulation in both animal 18 and human studies. 13 We hypothesised that combined angiotensin II (ATII) antagonism, by adding an AT 1 receptor antagonist to an ACE inhibitor, might provide a more complete block of the renin-angiotensin system. We therefore studied the effect of adding valsartan, 19 an ATII AT 1 receptor antagonist on early AWR and pulse pressure amplification in poorly controlled hypertensives already on ACE inhibitors.
Patients and methods

Patients
Eighteen patients (six men and 12 women) participated in the study. The mean age (mean ± s.d.) was 56 + 9 years (range 41 to 69). All the patients had inadequately controlled essential hypertension (Ͼ160/95 mm Hg) for the last 6 months and were on at least three antihypertensives always including an ACE inhibitor, diuretic (n = 16), calcium antagonists (n = 12), beta-blocker (n = 6), alpha-blocker (n = 4). The average dosages of ACE inhibitors being used were, captopril 100 mg and enalapril 20 mg. The mean Aug in the patients was 21 ± 8 mm Hg. An age-matched group of six hypertensives with an Aug of 10 ± 5 mm Hg was also studied concurrently over a 2-week period to show that the Aug did not change over time. Informed consent was obtained from all the patients and the study had institutional ethics committee permission.
Study design
The patients were studied in the fasting state and abstained from caffeine containing beverages and smoking in the 12 h prior to the study. The patients were studied at baseline and then at 2 h and 2 weeks following the oral administration of 80 mg of valsartan, an ATII, AT 1 receptor antagonist.
Blood pressure measurements
The haemodynamic measurements were made in a quiet room at 20-23°C and after a rest of 15 min in the recumbent position. Brachial blood pressure and heart rate were measured in the left arm with an automated digital oscillometric blood pressure monitor (Omron Model 705-CP). A mean of three readings was taken.
Derivation of arterial wave reflections
Immediately after taking the final blood pressure reading, the same arm was used for applanation tonometry. A micromanometer-tipped probe (Sphygmocor™ BPAS-1; PWV Medical, Sydney, Australia) was applied to the surface of the skin overlying the radial artery and the peripheral radial pulse continuously recorded. 20 The central aortic waveform is derived from radial tonometry and the peripheral brachial blood pressure, assuming that mean blood pressure is equal at both sites 9 by using a previously validated mathematical transformation within the software package (Sphygmocor™). 4, 21, 22 The aortic waveform was further analysed to yield the central systolic and diastolic blood pressure and calculate the augmentation pressure and augmentation index, both reflecting the degree of wave reflection and arterial stiffness ( Figure 1 ). The derived aortic waveform represents the sum of both incident and reflected waves. The early systolic peak (P 1 ) is the primary wave and corresponds with the timing of peak flow and the late systolic peak (P 2 ) is the result of the reflected wave returning from the peripheral site and causing an increase in amplitude of the pulse and aortic SBP. Augmentation pressure is the difference between the early and late Figure 1 Waveform printout of one of the study subjects showing exaggerated early wave reflection P 1 : Early systolic peak which corresponds to the time of peak flow or ejection P 2 : Late systolic peak is caused by wave reflection. The augmentation pressure (Aug) is the absolute difference between the P 1 and P 2 . The augmentation index (AIx) is defined as the difference between the early and late systolic peaks (⌬P) expressed as a percentage of pulse pressure (PP).
systolic peaks when expressed in absolute terms in mm Hg while the AIx is the difference between the two peaks expressed as percentage of total pulse height. The validity of these derived values has been confirmed by simultaneous direct central aortic measurements 21, 23 and is highly reproducible in both healthy and diseased populations. The withinobserver difference AIx is 0.49 ± 5.37% and the between-observer difference is 0.23 ± 3.80% for the AIx 24 and the between-observer difference for the Aug is 0.1 ± 2.1. 25 The pulse height variability (% of mean pulse height) was always less than 5% in our study.
Statistical analysis
The statistical analysis was performed through SAS (Statistical Analysis system for Windows) software. Time-dependent patterns of blood pressure changes, arterial wave reflection and pulse pressure amplification were tested by analysis of variance (ANOVA) of repeated measures. To adjust for the effect of calcium-channel blockers, the haemodynamic changes were analysed by two-way ANOVA of repeated measures, testing time and treatment interaction. We also correlated the effect of blood pressure change to the fall in augmentation pressure at each time point by ANOVA. Data are expressed as mean ±s.d., P Ͻ 0.05 considered significant.
Results
The addition of valsartan was well tolerated. One patient complained of dizziness and no patient withdrew from treatment.
Blood pressure and heart rate
Both brachial SBP and DBP decreased significantly with valsartan (P Ͻ 0.001) at 2 h and 2 weeks after starting therapy (Table 1) . There was no change in heart rate. There was no change in blood pressure, pulse pressure amplification or augmentation pressure in the control group of hypertensives.
Pulse pressure and early wave reflection
At baseline, aortic PP was significantly lower than brachial PP (P Ͻ 0.01). Both brachial (P Ͻ 0.05) and aortic PP (P Ͻ 0.01) decreased significantly follow- Table 1 Blood pressure (mm Hg) and heart rate before (baseline) and 2 h and 2 weeks following the addition of AII receptor blockade (n = 18, mean ± s.d. *P Ͻ 0.01 compared with baseline)
Peripheral (brachial)
Central ( Journal of Human Hypertension ing valsartan (Table 2 ). This decrease (Figure 2 ) occurred to a greater extent in the aortic than in the brachial PP (P Ͻ 0.05). There was a significant decrease in the amplitude of wave reflection, the augmentation pressure decreased from a baseline value of 21 ± 8 vs 11 ± 7 at 2 h to 10 ± 5 at the end of 2 weeks (P Ͻ 0.01). The augmentation index decreased from a baseline value of 34.8 ± 6 vs 22.1 ± 7 at 2 h to 21.9 ± 8 at the end of 2 weeks (P Ͻ 0.001). When the results were analysed separately to adjust for the group on calcium channel blockers, the augmentation pressure decreased from a baseline value of 18.1 ± 4.7 vs 10.1 ± 3.9 at 2 h to 11.2 ± 6.3 at the end of 2 weeks (n = 12, P Ͻ 0.01) in the group taking calcium channel blockers. In the group not on calcium channel blockers, the augmentation pressure was 23.75 ± 11 at baseline and decreased to 13 ± 10 at 2 h and 8.5 ± 3.1 at 2 weeks (n = 6, P Ͻ 0.001). There was a significant positive correlation in individual subjects between the fall in blood pressure and the fall in augmentation pressure (r = 0.59, P Ͻ 0.001) when compared between baseline and 2 weeks.
Pulse pressure amplification
Valsartan induced a greater fall in central systolic pressure than in peripheral pulse pressure (P Ͻ 0.05) with pulse pressure amplification increasing to normal values (P Ͻ 0.001) (Figure 3 ).
Discussion
As large artery stiffness increases in older subjects, SBP rises and DBP falls, with a resulting increase in PP. The normal greater amplification of PP between central and peripheral arteries gradually also decreases as a result of the augmentation of the central PP by early wave reflection. There is now increasing evidence that PP is an indicator of largeartery stiffness and an independent predictor of the risk of coronary heart disease, a relationship that is even stronger than with mean arterial pressure in middle-aged and older subjects. 26 Our results show the effects of adding an ATII AT 1 receptor antagonist to an ACE inhibitor on arterial wave reflections, pulse pressure and pulse pressure amplification in poorly controlled hypertensives: (i) Both SBP and DBP decreased significantly with no major adverse effects. (ii) There was a significant decrease in AWR in the ascending aorta. (iii) The central PP decreased significantly more than brachial PP with a significant increase in PP amplification.
Valsartan-induced effects on arterial wave reflection
The present study showed that in patients with poorly controlled hypertension, an ATII AT 1 receptor antagonist valsartan, when added to patients already on an ACE inhibitor, induced a marked reduction of AWR, producing a fall in late systolic peak in the aorta, associated with a reduction in both the augmentation pressure and index, which is largely due to fall in blood pressure but may partly be due to the effects of the drug on the arterial wall. There has been a recent surge in interest in drugs that not only reduce blood pressure but also modify the blood pressure curve. In this setting, nitrates, 27 calcium-channel blockers, 15 vasodilating beta-blockers 10 and ACE inhibitors [12] [13] [14] have all been shown to decrease AWR in the ascending aorta. This is in contrast to drugs that have no effect on AWR and arterial stiffness despite the same extent of blood pressure reduction. For instance, neither alphablockers 17 nor conventional beta-blockers 16 improve arterial wave reflection. Some beta-blockers might actually increase the amplitude of reflected waves acutely. 5 Arteriolar dilators have also shown only a modest effect on wave reflection. 5 The suggestion from our results is that ATII AT 1 receptor antagonists may also have a similar effect as ACE inhibitors and may provide additional benefit on arterial stiffness and AWR when used in combination with an ACE inhibitor. However, the augmentation pressure and index depend on three factors: wave reflection, pulse wave velocity and sites of wave reflection. As PWV has not been measured in this study, we cannot attribute the effects of ATII receptor antagonist wholly to decrease in wave reflection. Comparative studies incorporating both PWV and AWR measurements are needed to specifically answer this question.
Pulse pressure amplification
Haemodynamic studies have shown that whereas mean arterial pressure is relatively stable along the arterial tree, pulse pressure increases markedly from central to peripheral arteries. It has been found using invasive haemodynamic methods, that the radial aortic pressure difference in normotensive subjects aged 48-77 years approximates +12 to 20 mm for SBP and −1 mm for DBP. 4, 5 In our study population of hypertensive patients the mean amplification for SBP was 8 (±3 mm, s.d.) mm Hg.
As pulse pressure amplification is due to the progressive decrease in cross-sectional area and the increase in early wave reflection ongoing from large to small arteries, it is to be expected that drugs with vasodilator properties would modify pulse pressure amplification. Nitrates modify pulse pressure ampli-fication favourably due to their preferential effect on central more than peripheral pressure. 27 In genetically hypertensive rats that have equal central and peripheral pressures, giving ACE inhibitors or calcium-channel blockers restores the pulse pressure gradient but hydralazine does not. 18 However, there is evidence that ACE inhibitors, by causing an equal decrease in brachial and aortic PP may not actually increase PP amplification, despite reducing wave reflection in patients with essential hypertension 14 although some studies have shown a restoration of pulse pressure gradient in patients with end-stage renal disease. 13 In the present study, we have observed that valsartan when added to an ACE inhibitor, preferentially decreased central pulse pressure, favourably modifying pulse pressure amplification, restoring it to normal values.
Additive effects of ACE inhibition and angiotensin II receptor blockade
The important finding in our study is that ATII receptor blockade when added to ACE inhibitor, has beneficial haemodynamic effects not only on blood pressure (Table 1) but also on the important components of the blood pressure curve, namely, arterial wave reflection and PP amplification (Figure 3 ). Both ATII AT 1 receptor antagonists and ACE inhibitors affect the same pressor system, but because acting at different sites, they might have additive or synergistic effects. There are a number of theoretical reasons to support this view. Firstly, ACE inhibitors may not be able to maintain a continuous decrease in plasma ATII levels, which is due to: (i) reactive rise in plasma renin and ATI secondary to the interruption of ATII feedback on renin release; and (ii) the presence in the heart and blood vessel walls of other ATII forming pathways not responsive to ACE inhibitors. This phenomenon can be neutralised by ATII blockade. Secondly, the reactive rise in plasma ATII induced by AT 1 receptor blockade can be strongly inhibited by ACE inhibition. Therefore, addition of an AT 1 receptor antagonist to an ACE inhibitor might help to achieve a more powerful block of the renin-angiotensin system. Finally, the ancillary properties of both ACE inhibitors, eg, interruption of kinin metabolism and interaction with nitric oxide (NO), and of AT 1 receptor antagonists, eg, interaction with NO and prostaglandins may be active when the two agents are used singly, but may be synergistic when the groups are combined. 28 Additive effects on blood pressure and renin release in sodium-depleted normotensive adults 29 and on exercise capacity in heart failure patients 30 has been described recently when an ACE inhibitor is combined with an ATII AT 1 receptor antagonist. It may be argued that 12 of the patients were already on calcium channel blockers, which also have favourable effects on arterial wave reflection. However, we have shown that the six patients not taking calcium channel blockers also had a significant decrease in augmentation pressure.
The favourable effect on arterial wave reflections and PP amplification could represent either a structural change in the vessel walls involving reduction
Journal of Human Hypertension of growth of vascular smooth muscle cells in the vessel walls, as ATII promotes vascular hypertrophy independent of any blood pressure changes. 31 Moreover, AT 1 receptor antagonists have been shown to cause a blood pressure independent regression of left ventricular hypertrophy in hypertensive patients. 32 However, the duration of our study is too short to ascribe the beneficial effects to actual structural changes in the vessel wall and the fall in augmentation pressure was in part attributable to the decrease in blood pressure.
There may be a functional change in the vessel wall, especially in the endothelium. The endothelium is known to release vasoactive substances like NO and endothelin-1 (ET-1). Changes in vascular tone can alter arterial stiffness. 33 Glyceryl trinitrate, a source of NO, has been shown to cause changes in the arterial waveform indicative of reduced arterial stiffness. 24 NO modulates the generation of ATII and also acts as a functional antagonist at vascular smooth muscle cells. 34 Thus blocking the effects of ATII on vascular smooth muscle cells may lead to improved endothelial function. This antagonism between NO and the ATII system may explain the beneficial haemodynamic effects observed with the addition of ATII blockade to ACE inhibition leading to an improvement in endothelial dysfunction.
The small number of patients in our study as well as the fact that they were a select group of resistant hypertensives already on three drugs means that these results may not apply to all grades of hypertension. We need larger long-term comparative studies with agents producing similar hypotensive effect to extend such observations to hypertension in general. It may be argued that not all patients were on the maximum doses of ACE inhibitors, diuretics or calcium channel blockers, however the purpose of the study was to look at the effect of adding an ATII antagonist to patients already on therapy including an ACE inhibitor with resistant hypertension as this reflects more what is generally recommended 35 and is happening in clinical practice.
In conclusion, the addition of angiotensin II blockade to an ACE inhibitor in the setting of patients with poorly controlled hypertension significantly lowers blood pressure without any major adverse effects. Perhaps of greater interest are the favourable vascular effects reducing arterial wave reflection and increasing pulse pressure amplification. However, the data presented here is not definitive and we need larger, randomised clinical trials to answer this question.
